Cabenuva demonstrated superior efficacy in LATITUDE trial, ViiV Healthcare says

ViiV Healthcare reported that final 48-week data from the LATITUDE phase III trial showed its long-acting injectable, Cabenuva (cabotegravir + rilpivirine), maintained viral load suppression better than daily oral therapy in people with past adherence challenges; the results were published in the New England Journal of Medicine.

ViiV Healthcare reported final results from the LATITUDE phase III trial showing its long-acting injectable treatment, Cabenuva, maintained viral load suppression more effectively than daily oral therapy in people with a history of antiretroviral adherence challenges. The 48-week results were published in the New England Journal of Medicine. In February 2024 an independent Data and Safety Monitoring Board recommended halting randomisation and invited eligible participants to receive the long-acting cabotegravir plus rilpivirine regimen based on interim efficacy data. ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi as shareholders. Key findings: - Cabenuva (long-acting cabotegravir + rilpivirine) showed superior efficacy in maintaining viral load suppression versus daily oral therapy in the LATITUDE trial. - The reported results cover 48 weeks and were published in the New England Journal of Medicine. - An independent Data and Safety Monitoring Board recommended stopping randomisation in February 2024 and offered the long-acting regimen to eligible participants based on interim data. - ViiV Healthcare is majority owned by GSK, and Pfizer and Shionogi are shareholders. Summary: The LATITUDE data provide randomized evidence that a long-acting injectable regimen can better maintain viral suppression in the studied population. ViiV described the trial as the first randomized study confirming superiority of this regimen for people with adherence challenges. Undetermined at this time.